18.7 C
New York
Thursday, June 4, 2026

Tag: insulin

newssourceFORcompanyinformationcontent1marketreleases

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical Group Limited (HKEX Stock CodeL 1093) (“CSPC”) for SYH2086, a preclinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and orforglipron derivative. Madrigal plans to initiate clinical development in the first half of 2026.

SlumberSlim Launches Sleep-Centric Formula to Support Metabolic Balance and Circadian Health in Adults Over 35

New Non-Stimulant Supplement Aims to Complement Overnight Wellness Routines with Polyamine-Aligned Botanical Support 
New Non-Stimulant Supplement Aims to Complement Overnight Wellness Routines with Polyamine-Aligned Botanical Support

LipoVive Releases Ingredient Report Comparing Natural GLP-1 Support to Synthetic Drugs Like Mounjaro

A Plant-Based Formula With Science-Referenced Compounds Designed to Support Hormonal Weight Balance Without Prescription Medications 
A Plant-Based Formula With Science-Referenced Compounds Designed to Support Hormonal Weight Balance Without Prescription Medications

Trimology Weight Loss Unlocks Ancient Ugandan Ritual That Reactivates the Body’s Missing Fat-Burning Signal

New Scientific Discovery in Resistant Starch Awakens Metabolic Signals That Vanish After 35 — Helping Over 147,000 Women Reclaim Fat Loss Without Diets, Injections, or Tracking 
New Scientific Discovery in Resistant Starch Awakens Metabolic Signals That Vanish After 35 — Helping Over 147,000 Women Reclaim Fat Loss Without Diets, Injections, or Tracking

Belly Fat Burner: Why Men and Women are Using Strong Over the Counter Diet Supplements like PhenQ to Lose Stubborn Abdominal Fat

New York City, NY, July 29, 2025 (GLOBE NEWSWIRE) --

In 2025, PhenQ is setting a new standard for belly fat burners with its research-driven, natural solution, providing powerful, long-lasting support for a slimmer, healthier stomach without injections or unwanted side effects, and supporting a healthier, more sustainable lifestyle.

Menovelle ‘Coffee Hack’ Fixes Hot Flashes, Belly Weight Gain & Mood Swings, Research Suggests

A Natural Supplement Trend in 2025, Menovelle Helps Women Support Hormonal Balance and Metabolic Energy Without Hormone Therapy or Stimulants 
A Natural Supplement Trend in 2025, Menovelle Helps Women Support Hormonal Balance and Metabolic Energy Without Hormone Therapy or Stimulants

Sugar Land Medical Weight Loss Expert, Dr. Adelola Ashaye, Launches Metabolic Wellness & Healthy Weight Program at InTouch Primary Care

Dr. Adelola Ashaye has launched Metabolic Wellness & Healthy Weight Program at InTouch Primary Care, offering a personalized, medically guided approach to sustainable weight loss...

Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology

Company to Pursue Technologies to Improve Muscle Strength, Bone Health, and Other Longevity Indicators NEW YORK, July 24, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO)...

Medtronic secures CE Mark for MiniMed™ 780G System for insulin-requiring people with diabetes including expanded indications in children as young as two, during pregnancy,...

GALWAY, Ireland, July 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in medical technology, today announced CE (Conformité Européenne) Mark in...

Blue Circle Health expands type 1 diabetes care program to Louisiana

Free type 1 diabetes clinical care, education, and support program for adults is now operating in Louisiana.Designed to improve health outcomes and empower individuals...

Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society’s Annual...

Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achieved clinically meaningful weight reductionsSubstantial improvements in insulin resistance were also...

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025

Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInsulin

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers